Aldeyra Therapeutics News and Activities
Presence
Aldeyra Therapeutics develops medicines for immune and metabolic diseases. It provides drug research and clinical development services for patients, healthcare providers, and partners in eye disease and other inflammatory conditions.
Aldeyra Therapeutics products and services overview:
- Eye disease therapies
- Inflammation treatments
- Metabolic disease drugs
- Clinical development services
Revenue: ~$0 million
Employees: 110
Headquarters: Lexington, United States (USA)
Aldeyra Therapeutics is one of the...
Aldeyra Therapeutics is a company listed under the stock ticker ALDX (US).
Executives
View the org chart displaying its 11 main executives
Most searched biographies at Aldeyra Therapeutics
- Todd Brady, Chief Executive Officer, President and Director
- Martin Joyce, Director
- Ben Bronstein, Director
Popular executive movements at Aldeyra Therapeutics
- Stephen Machatha, Chief Development Officer, will leave the company on Mar. 31, 2026 (posted on January 2 2026).
Create your alert
to follow the executive moves at Aldeyra Therapeutics.
Biotechnology
Aldeyra Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Aldeyra Therapeutics
- Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial | Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap | Aldeyra Therapeutics, Inc.
- Press Releases | Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference | Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease | Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease | Aldeyra Therapeutics, Inc.
- Press Releases | Aldeyra Therapeutics, Inc.
- Press Releases | Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease | Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference | Aldeyra Therapeutics, Inc.
- View more press releases Close
Social media about Aldeyra Therapeutics
- Aldeyra Therapeutics on Wikipedia, Google News & Yahoo Finance
- Aldeyra Therapeutics on LinkedIn, X (Twitter) & YouTube
